Mission
Why TrialLineage exists
Most people only see the endpoint of biomedical science: a new drug, a trial announcement, or a breakthrough headline.
TrialLineage restores the hidden story: the basic science, failed hypotheses, model systems, technologies, and people behind progress.
Every clinical trial has a lineage. Every approved therapy rests on decades of prior work — discoveries that are rarely explained, poorly connected in public discourse, and often invisible to the people who benefit most from the result.
The problem we address
Science reporting tends to cover endpoints: a drug is approved, a trial succeeds, a company announces results. This creates a distorted impression of how breakthroughs happen.
The actual structure is more like an inverted tree. A single clinical breakthrough may depend on structural biology from the 1990s, a mouse model developed in 2004, a screening method published in 2011, and a translational insight that took five years to validate.
Without making that structure visible, the public loses the ability to understand where progress comes from, why it takes time, and why investing in basic science matters.
What we believe
- Scientific progress is cumulative. No breakthrough is isolated.
- The public deserves access to the reasoning behind medical advances, not just the conclusions.
- Explaining lineage honestly — including failed paths and open questions — builds trust in science better than hype does.
- A public library of scientific histories can serve patients, students, journalists, policymakers, and researchers.
- Independence from industry and advocacy groups is non-negotiable for credibility.
Where we are now
TrialLineage is in early build. The first case page is live, concept explainers are growing, and new lineage investigations are being identified through ongoing research review.
We are building this as a public resource funded by individual supporters, not industry sponsors.